Literature DB >> 15735491

Laparoscopic antireflux procedures in the management of gastroesophageal reflux following esophageal atresia repair.

Ciro Esposito1, Jacob C Langer, Klaus Schaarschmidt, Girolamo Mattioli, Carolien Sauer, Antonella Centonze, Bruno Cigliano, Alessandro Settimi, Vincenzo Jasonni.   

Abstract

OBJECTIVES: The validity of open fundoplication after esophageal atresia (EA) repair is still disputed. The authors have retrospectively evaluated the results achieved in their centers using laparoscopic antireflux procedures (LARP) in children operated for EA at birth.
METHODS: From 1998 to 2002, 350 children underwent LARP. Of these, 21 (6%) underwent EA repair at birth. Our study focused only on the management of these 21 patients; 5 of them (23.8%) were neurologically impaired children (NIC). All underwent LARP, 9 patients according to Nissen, 9 according to Thal, and 3 according to Toupet. The 5 NIC with feeding problems underwent concomitant g-tube placement during the same procedure.
RESULTS: All the procedures were completed in laparoscopy, without intraoperative complications. The mean operative time was 65 minutes (range 45-140). We had no mortality in our series. Hospital stay varied from 2 to 9 days (median 3 days). At a maximum follow-up of 6 years, all patients were evaluated with a 24-hours pH-metry and barium swallow. The 16 neurologically normal children were free of symptoms at the last follow-up; five of them (31.2%) had mild dysphagia, which disappeared spontaneously within 3-6 months. One girl experienced an important episode of aspiration 2 years after the LARP, although there was no evidence of reflux at the follow-up examinations. As for the 5 NIC, one patient eats only through a g-tube, the other 4 undergo mixed feeding (g-tube and mouth); none have signs of GER, but two of them still present respiratory symptoms, and one has delayed gastric emptying.
CONCLUSIONS: In our experience laparoscopic antireflux surgery is an appropriate treatment of GER in children operated for EA at birth, independently of the antireflux mechanism adopted; the 31.2% rate of short-term dysphagia presenting as residual respiratory symptoms may be due to a primary dysmotility of the esophagus consequent to the esophageal atresia.

Entities:  

Mesh:

Year:  2005        PMID: 15735491     DOI: 10.1097/01.mpg.0000151761.43664.b2

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  6 in total

Review 1.  The current role of laparoscopic surgery for gastroesophageal reflux disease in infants and children.

Authors:  T E Lobe
Journal:  Surg Endosc       Date:  2007-01-02       Impact factor: 4.584

2.  Thoracoscopic repair of esophageal atresia and tracheoesophageal fistula: a multi-institutional analysis.

Authors:  George W Holcomb; Steven S Rothenberg; Klaas M A Bax; Marcelo Martinez-Ferro; Craig T Albanese; Daniel J Ostlie; David C van Der Zee; C K Yeung
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

Review 3.  Laparoscopic fundoplication for gastroesophageal reflux disease in infants and children.

Authors:  Tadashi Iwanaka; Yutaka Kanamori; Masahiko Sugiyama; Makoto Komura; Yujiro Tanaka; Tetsuro Kodaka; Tetsuya Ishimaru
Journal:  Surg Today       Date:  2010-04-28       Impact factor: 2.549

4.  Management of Gastroesophageal Reflux Disease in Esophageal Atresia Patients: A Cross-Sectional Survey amongst International Clinicians.

Authors:  Marinde van Lennep; Frederic Gottrand; Christophe Faure; Taher I Omari; Marc A Benninga; Michiel P van Wijk; Usha Krishnan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2022-06-07       Impact factor: 3.288

Review 5.  Impact of changing epidemiology of gastroesophageal reflux disease on its diagnosis and treatment.

Authors:  Hugo Bonatti; Sami R Achem; Ronald A Hinder
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452

Review 6.  Fundoplication in Patients with Esophageal Atresia: Patient Selection, Indications, and Outcomes.

Authors:  Risto J Rintala
Journal:  Front Pediatr       Date:  2017-05-15       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.